ACSO abstract drop moves stocks

The scrutiny over abstracts submitted for the upcoming (May 30 - June 3) American Society of Clinical Oncology meeting boosts Clovis Oncology (CLVS8% premarket but shaves Incyte (INCY10%.

Traders are selling INCY on modest volume apparently in response to its abstract on ruxolitinib with capecitabine as a second-line therapy for metastatic pancreatic cancer. In a Phase 2 trial, the drug had no observable effect on Overall Survival and Progression Free Survival in patients with C-reactive protein levels less than or equal to 13 mg/dl.

Traders are buying CLVS in modest volume apparently in response to its Phase 1/2a study of lucitanib in advanced solid tumors. Clinical activity was observed in all doses from 5 mg - 30mg with tolerable side-effect profiles.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs